AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript
AstraZeneca PLC ( AZN ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Andrew Barnett - Head of Investor Relations Pascal Soriot - CEO & Executive Director Aradhana Sarin - CFO & Executive Director David Fredrickson - Executive Vice-President of Oncology Haematology Business Unit Susan Galbraith - Executive Vice President of Oncology R&D Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D Marc Dunoyer - CEO of Alexion & Chief Strategy Officer Conference Call Participants Michael Leuchten - Jefferies LLC, Research Division Sarita Kapila - Morgan Stanley, Research Division Justin Smith Sachin Jain - BofA Securities, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Peter Verdult - BNP Paribas, Research Division Mattias Häggblom - Handelsbanken Capital Markets AB, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Matthew Weston - UBS Investment Bank, Research Division Steve Scala - TD Cowen, Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division Gonzalo Artiach Castanon - Danske Bank A/S, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Presentation Operator Good afternoon, and welcome to AstraZeneca's 9 months and Q3 2025 webinar for investors and analysts.
AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)
The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. AstraZeneca's financials remain robust, with double-digit revenue and EPS growth, but Q4 2025 is expected to show slower or even negative EPS growth. Risks could also stem from U.S. pricing pressures and potentially unresolved tax issues in China. Additionally, stretched valuations and limited near-term upside, prompt a Hold rating.
AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform
AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.
AstraZeneca climbs to net all-time high after US deal reassurance
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted what analysts called a very solid set of third-quarter results, but the shares barely moved in early morning trading as the City waited for more details on the analyst call. In afternoon trading, shares in the giant drugmaker jumped over 4% to a new all time high above 12,990p.
Compared to Estimates, Astrazeneca (AZN) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AstraZeneca's strong U.S. ties reflect Trump's policy of equalization, says CEO
AstraZeneca CEO Pascal Soriot discusses Q3 earnings and the pharma giant's relationship with the U.S. administration.
AstraZeneca grows faster than expected but maintains guidance
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted a confident set of third-quarter results, not only beating revenue and core earnings forecasts, but also hailing "strong underlying momentum" across the business to set up growth through next year as well. The FTSE 100 pharmaceutical group generated revenues of $15.19 billion in the three months to 30 September, up 12% compared to a year ago and beating the consensus forecast of $14.8 billion.
AstraZeneca beats third-quarter revenue and profit expectations
AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney disease drugs, prompting London's most valuable listed company to retain its full-year forecasts.
AstraZeneca wins shareholder backing for NYSE listing in US pivot
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
AstraZeneca to face questions on Trump MFN deal, patent expiries and pipeline
When AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) reports third-quarter results next Thursday, 6 November, with investors and analysts will be keen to hear about the financial implications of the 'most favoured nation' (MFN) pricing deal recently agreed with Donald Trump, as well as the loss of its Farxiga patent and prospects for new drugs coming out of its pipeline. This will be the first opportunity for discussion of the US MFN deal, making its a key discussion point, according to analysts at UBS.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
Astrazeneca (AZN) closed at $82.61 in the latest trading session, marking a -1.72% move from the prior day.
